Barclays PLC Purchases Shares of 5,700 Pharvaris (NASDAQ:PHVS)

Barclays PLC purchased a new stake in Pharvaris (NASDAQ:PHVS) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 5,700 shares of the company’s stock, valued at approximately $106,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in Pharvaris during the 3rd quarter worth about $526,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pharvaris during the 3rd quarter worth about $906,000. State Street Corp acquired a new stake in Pharvaris during the 3rd quarter worth about $1,000,000. Novo Holdings A S raised its holdings in Pharvaris by 47.7% during the 2nd quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock worth $32,430,000 after buying an additional 556,970 shares during the period. Finally, Sofinnova Investments Inc. raised its holdings in Pharvaris by 2.9% during the 2nd quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock worth $11,309,000 after buying an additional 16,862 shares during the period.

Pharvaris Price Performance

Shares of PHVS opened at $18.54 on Thursday. The company has a market capitalization of $590.31 million, a price-to-earnings ratio of -6.62 and a beta of -3.06. Pharvaris has a fifty-two week low of $15.37 and a fifty-two week high of $33.00. The business’s 50-day moving average is $20.38 and its 200-day moving average is $19.36.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.